Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives $32.44 Average PT from Analysts

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has received a consensus recommendation of “Moderate Buy” from the twelve analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $32.70.

A number of brokerages have commented on AARD. Raymond James Financial started coverage on shares of Aardvark Therapeutics in a report on Tuesday, December 2nd. They issued a “strong-buy” rating and a $47.00 price objective on the stock. BTIG Research initiated coverage on Aardvark Therapeutics in a research report on Friday, November 7th. They set a “buy” rating and a $26.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research note on Monday, December 22nd. William Blair began coverage on Aardvark Therapeutics in a report on Friday, December 12th. They issued an “outperform” rating for the company. Finally, Jones Trading assumed coverage on Aardvark Therapeutics in a report on Wednesday, October 1st. They set a “buy” rating and a $33.00 price objective on the stock.

Insiders Place Their Bets

In related news, CEO Tien-Li Lee acquired 7,000 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was bought at an average cost of $14.48 per share, with a total value of $101,360.00. Following the acquisition, the chief executive officer directly owned 1,551,613 shares in the company, valued at approximately $22,467,356.24. The trade was a 0.45% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Nelson Sun bought 3,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $14.40 per share, for a total transaction of $43,200.00. Following the purchase, the chief financial officer owned 108,484 shares in the company, valued at approximately $1,562,169.60. This represents a 2.84% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Hedge Funds Weigh In On Aardvark Therapeutics

A number of hedge funds have recently bought and sold shares of AARD. Goldman Sachs Group Inc. acquired a new position in shares of Aardvark Therapeutics in the 1st quarter worth approximately $153,000. Adage Capital Partners GP L.L.C. bought a new position in Aardvark Therapeutics during the first quarter worth $1,878,000. Cormorant Asset Management LP bought a new position in Aardvark Therapeutics during the first quarter worth $6,009,000. Walleye Capital LLC acquired a new position in Aardvark Therapeutics in the first quarter worth $88,000. Finally, Braidwell LP bought a new stake in Aardvark Therapeutics during the first quarter valued at $3,755,000.

Aardvark Therapeutics Stock Performance

Aardvark Therapeutics stock opened at $13.65 on Monday. The firm has a market capitalization of $297.16 million and a PE ratio of -6.44. Aardvark Therapeutics has a one year low of $4.88 and a one year high of $19.58. The stock’s 50 day moving average price is $11.65 and its 200 day moving average price is $11.91.

Aardvark Therapeutics (NASDAQ:AARD) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.07.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.